Pangaea Oncology Past Earnings Performance

Past criteria checks 0/6

Pangaea Oncology's earnings have been declining at an average annual rate of -8.2%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 15.3% per year.

Key information

-8.2%

Earnings growth rate

22.4%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate15.3%
Return on equity-32.6%
Net Margin-37.0%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Is Pangaea Oncology (BME:PANG) Weighed On By Its Debt Load?

Nov 09
Is Pangaea Oncology (BME:PANG) Weighed On By Its Debt Load?

Pangaea Oncology, S.A.'s (BME:PANG) About To Shift From Loss To Profit

May 17
Pangaea Oncology, S.A.'s (BME:PANG) About To Shift From Loss To Profit

Analysts Expect Pangaea Oncology, S.A. (BME:PANG) To Breakeven Soon

Feb 01
Analysts Expect Pangaea Oncology, S.A. (BME:PANG) To Breakeven Soon

Revenue & Expenses Breakdown

How Pangaea Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BME:PANG Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2414-5130
31 Mar 2412-5110
31 Dec 2310-590
30 Sep 238-480
30 Jun 237-360
31 Mar 237-360
31 Dec 227-350
30 Sep 227-250
30 Jun 227-250
31 Mar 227-150
31 Dec 217-140
30 Sep 217-140
30 Jun 217-140
31 Mar 216-140
31 Dec 206-240
30 Sep 206-340
30 Jun 206-440
31 Mar 206-440
31 Dec 196-540
30 Sep 196-340
30 Jun 195-240
31 Mar 196-140
31 Dec 186-140
30 Sep 186-240
30 Jun 186-240
31 Mar 186-240
31 Dec 176-240
30 Sep 176-140
30 Jun 175-140
31 Mar 175-140
31 Dec 165-140
30 Sep 165-140
30 Jun 165030
31 Mar 164030
31 Dec 154030
31 Dec 142030
31 Dec 133030

Quality Earnings: PANG is currently unprofitable.

Growing Profit Margin: PANG is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PANG is unprofitable, and losses have increased over the past 5 years at a rate of 8.2% per year.

Accelerating Growth: Unable to compare PANG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PANG is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (5.4%).


Return on Equity

High ROE: PANG has a negative Return on Equity (-32.56%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies